These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32349020)

  • 21. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
    Katz AJ; Santoro M; Diblasio F; Ashley R
    Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
    Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
    Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
    Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Helical tomotherapy for prostate cancer radiation therapy: An audit of early toxicity and quality of life.
    Kunheri B; Lakshmi JS; Ravindran GC; Haridas ; Marwaha V
    J Cancer Res Ther; 2021; 17(2):366-371. PubMed ID: 34121678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
    Musunuru HB; Quon H; Davidson M; Cheung P; Zhang L; D'Alimonte L; Deabreu A; Mamedov A; Loblaw A
    Radiother Oncol; 2016 Jan; 118(1):112-7. PubMed ID: 26796591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
    Kim YJ; Ahn H; Kim CS; Kim YS
    Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
    Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
    Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
    Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
    Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
    Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126.
    Alexander GS; Krc RF; Assif JW; Sun K; Molitoris JK; Tran P; Rana Z; Mishra MV
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):990-998. PubMed ID: 38825251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
    Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
    Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.
    Wages NA; Sanders JC; Smith A; Wood S; Anscher MS; Varhegyi N; Krupski TL; Harris TJ; Showalter TN
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1254-1262. PubMed ID: 33227441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
    Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic body radiotherapy for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    BMC Urol; 2010 Feb; 10():1. PubMed ID: 20122161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
    Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
    Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison.
    Ogita M; Yamashita H; Nozawa Y; Ozaki S; Sawayanagi S; Ohta T; Nakagawa K
    Radiat Oncol; 2021 Jun; 16(1):107. PubMed ID: 34118956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.